Other efforts are exploring the potential role of IG in treating systemic inflammatory syndromes. CSL also continues its commitment to innovate for patients with Hereditary Angioedema (HAE).We recently set a new standard of care in HAE through the launch the world’s first subcutaneous preventative treatment. Further supporting our commitment to patients with HAE, we have initiated a Phase II clinical program to provide long acting prophylaxis via an anti- Factor XIIa monoclonal antibody, CSL312. Additional investments in HAE include a program developing a highly differentiated recombinant C1 Esterase Inhibitor (C1-INH) which could further improve the quality of life for patients with HAE.
On this strong base of product and disease expertise, CSL is leveraging its immunology expertise into programs in several new diseases and mechanistic pathways. We are embarking on Phase II/III programs in Dermatomyositis and Scleroderma, two major areas of unmet need. Meanwhile, CSL324, CSL’s anti-GCSF receptor monoclonal antibody is now being trialed in inflammatory skin disease, and early plans are in place for further studies in other neutrophil-mediated inflammatory conditions. We are also continuing to explore the therapeutic potential of CSL362 (a monoclonal antibody targeting CD123, or the IL3 receptor alpha) and CSL730 (a recombinant Fc-multimer); both mechanisms have the potential to impact a variety of auto-immune conditions. CSL Behring is committed to building on our deep knowledge and expertise in chronic and serious immunologic and neurologic diseases with the goal of saving lives and addressing the unmet need of patients worldwide.